Melior Enters Research Collaboration With Pfizer

Apr 09, 2007, 01:00 ET from Melior Discovery, Inc.

    EXTON, Pa., April 9 /PRNewswire-FirstCall/ -- Melior Discovery, Inc.
 announced today that it has signed an agreement with Pfizer, Inc., under
 which Melior's in vivo theraTRACE indications discovery platform will be
 used to evaluate the activity of selected Pfizer compounds.
     "Our agreement represents a significant opportunity for Melior to
 deliver value to Pfizer through the application of our unique and
 innovative in vivo testing platform," said Andrew Reaume, PhD, President
 and CEO of Melior. "We look forward to a productive collaboration."
     Melior Discovery Overview
     Melior Discovery is leading the transformation of pharmaceutical drug
 repositioning with its unique theraTRACE platform of multiplexed in vivo
 models. It is using this capability to both build an internal pipeline of
 development candidates as well as sharing this capability with pharma and
 biotechnology company partners. In the former case, Melior is identifying
 "privileged" compounds that have been discontinued by others which it
 identifies through a close working relationship with Dr. Christopher
 Lipinski. In its partnered arrangements, Melior offers pharmaceutical
 partners an approach to expand their late-stage pipelines with safe,
 high-quality drug candidates.
 
 

SOURCE Melior Discovery, Inc.
    EXTON, Pa., April 9 /PRNewswire-FirstCall/ -- Melior Discovery, Inc.
 announced today that it has signed an agreement with Pfizer, Inc., under
 which Melior's in vivo theraTRACE indications discovery platform will be
 used to evaluate the activity of selected Pfizer compounds.
     "Our agreement represents a significant opportunity for Melior to
 deliver value to Pfizer through the application of our unique and
 innovative in vivo testing platform," said Andrew Reaume, PhD, President
 and CEO of Melior. "We look forward to a productive collaboration."
     Melior Discovery Overview
     Melior Discovery is leading the transformation of pharmaceutical drug
 repositioning with its unique theraTRACE platform of multiplexed in vivo
 models. It is using this capability to both build an internal pipeline of
 development candidates as well as sharing this capability with pharma and
 biotechnology company partners. In the former case, Melior is identifying
 "privileged" compounds that have been discontinued by others which it
 identifies through a close working relationship with Dr. Christopher
 Lipinski. In its partnered arrangements, Melior offers pharmaceutical
 partners an approach to expand their late-stage pipelines with safe,
 high-quality drug candidates.
 
 SOURCE Melior Discovery, Inc.